PT-141 (Bremelanotide) is a cyclic peptide analog of alpha-MSH that acts as a non-selective melanocortin receptor agonist with activity at MC3R and MC4R. Bremelanotide was FDA-approved in 2019 (as Vyleesi) for hypoactive sexual desire disorder.
Sequence
cyclo[Nle-Asp-His-D-Phe-Arg-Trp-Lys]
Molecular Weight
1,025.18 g/mol
Half-life (Preclinical)
~2.7 hours (human, FDA-approved form)
Mechanism
MC3R and MC4R agonist; central nervous system mediated arousal pathway activation
Storage
-20°C lyophilized
Solubility
Sterile water
Research Summary
As an FDA-approved compound, PT-141 has extensive human clinical trial data published. In RUO research, it serves as a useful pharmacological tool for studying melanocortin receptor biology and central arousal pathways.
Research Strengths
FDA-approved analog (Vyleesi)
Extensive human clinical data
Well-characterized melanocortin pharmacology
Central mechanism of action
Limitations & Considerations
Nausea reported in human studies
Transient blood pressure changes noted
Regulatory considerations for RUO use
This information is for research reference only. PT-141 is a Research Use Only (RUO) compound not approved for human or veterinary use. This does not constitute medical advice.